基因编辑技术重大突破，多家上市公司布局

Core Viewpoint - The research team from Uppsala University in Sweden has successfully demonstrated the survival and functionality of donor pancreatic β cells obtained through CRISPR-Cas gene editing technology in a type 1 diabetes patient for 12 weeks without the use of immunosuppressants, indicating a potential breakthrough in curing type 1 diabetes [1] Industry Summary - Over 20 listed companies in the A-share market are involved in gene editing technology [1] - According to data from Zhitongcaijing, a total of 21 gene editing concept stocks have received "positive" ratings from institutions, including buy, increase, and strong recommendation ratings [1] - Among these, Shenguan Medical (300888) is the most favored by institutions, with 27 institutional research reports mentioning this stock [1]